Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 92

Sort by

Sort Order Select

Journal Articles

Abstract 6226: Therapeutic vulnerability of MTAP-deleted nasopharyngeal carcinoma by MAT2A inhibitors

YUK-Yu Chan, Chi-Man Tsang, Grace T.Y. Chung, Ka-Fai To, Yi Zhang, Xiaodong Zhang, Jun Tang, Kwok Wai Lo

Cancer Res (2023) 83 (7_Supplement): 6226.

https://doi.org/10.1158/1538-7445.AM2023-6226

Published: 04 April 2023

View article titled, Abstract 6226: Therapeutic vulnerability of <em>MTAP</em>-deleted nasopharyngeal carcinoma by MAT2A inhibitors

Journal Articles

Abstract OT2-22-01: Epirubicin, cyclophosphamide and pyrotinib followed by docetaxel, trastuzumab and pyrotinib as neoadjuvant therapy for stage II-III HER2-positive breast cancer: a single-arm, multicenter phase 2 trial

Cancer Res (2023) 83 (5_Supplement): OT2-22-01.

https://doi.org/10.1158/1538-7445.SABCS22-OT2-22-01

Published: 01 March 2023

View article titled, Abstract OT2-22-01: Epirubicin, cyclophosphamide and pyrotinib followed by docetaxel, trastuzumab and pyrotinib as neoadjuvant therapy for stage II-III HER2-positive breast cancer: a single-arm, multicenter phase 2 trial

Journal Articles

Abstract P2-03-13: Breast Cancer Index (BCI) identifies fewer patients with high risk of late recurrence and high likelihood of benefit from extended endocrine therapy with invasive lobular compared to invasive ductal carcinoma

Otto Metzger, Neeta Parimi, Natalia Siuliukina, Yi Zhang, Kai Treuner, Gerrit-Jan Liefers

Cancer Res (2023) 83 (5_Supplement): P2-03-13.

https://doi.org/10.1158/1538-7445.SABCS22-P2-03-13

Published: 01 March 2023

View article titled, Abstract P2-03-13: Breast Cancer Index (BCI) identifies fewer patients with high risk of late recurrence and high likelihood of benefit from extended endocrine therapy with invasive lobular compared to invasive ductal carcinoma

Journal Articles

Abstract P2-11-10: Validation of the Breast Cancer Index (BCI) prognostic models optimized for late distant recurrence in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial

John MS Bartlett, Keying Xu, Jenna Wong, Gregory R. Pond, Yi Zhang, Melanie Spears, Ranelle Salunga, Elizabeth Mallon, Karen J. Taylor, Annette Hasenburg, Christos Markopoulos, Luc Dirix, Caroline Seynaeve, Cornelis J.H. van de Velde, Daniel Rea, Catherine A. Schnabel, Kai Treuner, Jane Bayani

Cancer Res (2023) 83 (5_Supplement): P2-11-10.

https://doi.org/10.1158/1538-7445.SABCS22-P2-11-10

Published: 01 March 2023

View article titled, Abstract P2-11-10: Validation of the Breast Cancer Index (BCI) prognostic models optimized for late distant recurrence in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial

Journal Articles

Abstract P2-03-02: Prospective assessment of the decision-making impact of the Breast Cancer Index in the BCI Registry Study

Tara B. Sanft, Jenna Wong, Brandon O’Neal, Natalia Siuliukina, Rachel C. Jankowitz, Mark Pegram, Jenny Fox, Yi Zhang, Kai Treuner, Joyce O’Shaughnessy

Cancer Res (2023) 83 (5_Supplement): P2-03-02.

https://doi.org/10.1158/1538-7445.SABCS22-P2-03-02

Published: 01 March 2023

View article titled, Abstract P2-03-02: Prospective assessment of the decision-making impact of the Breast Cancer Index in the BCI Registry Study

Journal Articles

Abstract P5-02-52: Predictive and prognosis value of PIK3CA mutations in HER2-positive breast cancer treated with tyrosine kinase inhibitors (TKIs): a systemic review and meta-analysis

Qiyun Shi, Juncheng Xuhong, Hao Tian, Yi Zhang, Jun Jiang, Xiaowei Qi

Cancer Res (2023) 83 (5_Supplement): P5-02-52.

https://doi.org/10.1158/1538-7445.SABCS22-P5-02-52

Published: 01 March 2023

View article titled, Abstract P5-02-52: Predictive and prognosis value of PIK3CA mutations in HER2-positive breast cancer treated with tyrosine kinase inhibitors (TKIs): a systemic review and meta-analysis

Journal Articles

Abstract P5-10-01: Phase 2 study of anlotinib combined with taxanes and lobaplatin in the neoadjuvant treatment of triple-negative breast cancer: efficacy, safety and biomarker analysis from the SWH-B006 (neoALTALL) trial

Cancer Res (2023) 83 (5_Supplement): P5-10-01.

https://doi.org/10.1158/1538-7445.SABCS22-P5-10-01

Published: 01 March 2023

View article titled, Abstract P5-10-01: Phase 2 study of anlotinib combined with taxanes and lobaplatin in the neoadjuvant treatment of triple-negative breast cancer: efficacy, safety and biomarker analysis from the SWH-B006 (neoALTALL) trial

Journal Articles

Abstract GS1-06: Evaluation of the Breast Cancer Index in premenopausal women with early-stage HR+ breast cancer in the SOFT trial

Ruth O’Regan, Yi Zhang, Gini F. Fleming, Prudence Francis, Roswitha Kammler, Giuseppe Viale, István Láng, Meritxell Bellet Ezquerra, Hervé R. Bonnefoi, Sherene Loi, Marco Colleoni, Catherine A. Schnabel, Kai Treuner, Meredith Regan

Cancer Res (2023) 83 (5_Supplement): GS1-06.

https://doi.org/10.1158/1538-7445.SABCS22-GS1-06

Published: 01 March 2023

View article titled, Abstract GS1-06: Evaluation of the Breast Cancer Index in premenopausal women with early-stage HR+ breast cancer in the SOFT trial

Journal Articles

Abstract P1-11-18: The efficacy and safety of trastuzumab and pertuzumab in combination with different chemotherapy regimens for neoadjuvant treatment of HER2-posotive breast cancer: a multi-center real-world study in China

Xiaowei Qi, Hong Hu, chen wenlin, xu yan, liu shu, fang yanman, Taolang Li, ming jia, zhou sihai, chai fan, liang yueyang, fan yuanming, Yi Zhang, Peng Tang, jiang jun, nie jianyun, Li Chen, Shushu Wang

Cancer Res (2023) 83 (5_Supplement): P1-11-18.

https://doi.org/10.1158/1538-7445.SABCS22-P1-11-18

Published: 01 March 2023

View article titled, Abstract P1-11-18: The efficacy and safety of trastuzumab and pertuzumab in combination with different chemotherapy regimens for neoadjuvant treatment of HER2-posotive breast cancer: a multi-center real-world study in China

Journal Articles

And-1 Coordinates with the FANCM Complex to Regulate Fanconi Anemia Signaling and Cisplatin Resistance

Yi Zhang, Jing Li, Yuan Zhou, Zhuqing Li, Changmin Peng, Huadong Pei, Wenge Zhu

Cancer Res (2022) 82 (18): 3249–3262.

https://doi.org/10.1158/0008-5472.CAN-22-0769

Published: 16 September 2022

View article titled, And-1 Coordinates with the FANCM Complex to Regulate Fanconi Anemia Signaling and Cisplatin Resistance

Includes: Supplementary data

Journal Articles

Abstract 5499: Efficacy of icotinib as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE)

Kun Qian, Bin Hu, Ming He, Zi-Tong Wang, Yu Liu, Hua-Gang Liang, Zhi-Yong Su, Yu-Shang Cui, Li-Jun Liu, Yi Zhang

Cancer Res (2022) 82 (12_Supplement): 5499.

https://doi.org/10.1158/1538-7445.AM2022-5499

Published: 15 June 2022

View article titled, Abstract 5499: Efficacy of icotinib as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE)

Journal Articles

Abstract 6147: Immune population changes in mammary adipose tissue during the development of obesity and their influence on triple negative breast cancer progression

Shimeng Liu, Yi Zhang, Myles Brown

Cancer Res (2022) 82 (12_Supplement): 6147.

https://doi.org/10.1158/1538-7445.AM2022-6147

Published: 15 June 2022

View article titled, Abstract 6147: Immune population changes in mammary adipose tissue during the development of obesity and their influence on triple negative breast cancer progression

Journal Articles

Abstract 4221: Characterization of OVA-expressing immunogenic syngeneic tumor models for immune checkpoint inhibitor evaluation

Chenpan Nie, Yi Zhang, Jia Zheng, Annie X. An, Jun Zhou, Henry Q.X. Li, Jingjing Wang

Cancer Res (2022) 82 (12_Supplement): 4221.

https://doi.org/10.1158/1538-7445.AM2022-4221

Published: 15 June 2022

View article titled, Abstract 4221: Characterization of OVA-expressing immunogenic syngeneic tumor models for immune checkpoint inhibitor evaluation

Journal Articles

Abstract 421: PLX-3618, a potent, selective monovalent BRD4 degrader demonstrates activity in models of prostate cancer

Kenneth Steadman, Gregory S. Parker, Geoffray Leriche, Sarah Fish, Julia Toth, Mary E. Spalding, Elizabeth Daniele, Aleksandar Jamborcic, Xiaoming Li, E Adam Kallel, Farhana Barmare, Kenneth Chng, Erika Green, Michael Hocker, Elliot Imler, Yi Zhang, Peggy A. Thompson, Simon Bailey

Cancer Res (2022) 82 (12_Supplement): 421.

https://doi.org/10.1158/1538-7445.AM2022-421

Published: 15 June 2022

View article titled, Abstract 421: PLX-3618, a potent, selective monovalent BRD4 degrader demonstrates activity in models of prostate cancer

Journal Articles

Abstract PD15-04: Breast Cancer Index and assessment of the Net Treatment Benefit (NTB) of extended endocrine therapy in HR+ breast cancer

Marc Buyse, Jenna Wong, Samuel Salvaggio, Jean-Christophe Chiem, Yi Zhang, Kai Treuner, Elma Meershoek-Klein Kranenbarg, Mickaël De Backer, Gerrit-Jan Liefers, Catherine A Schnabel

Cancer Res (2022) 82 (4_Supplement): PD15-04.

https://doi.org/10.1158/1538-7445.SABCS21-PD15-04

Published: 15 February 2022

View article titled, Abstract PD15-04: Breast Cancer Index and assessment of the Net Treatment Benefit (NTB) of extended endocrine therapy in HR+ breast cancer

Journal Articles

Abstract PD9-09: Breast cancer index and assessment of tumor proliferation by molecular grade index (MGI) within distinct HOXB13/IL17BR (H/I) subsets

Reshma Mahtani, Yuan Yuan, Kari B Wisinski, Jay Morris, Max Salganik, Yi Zhang, Catherine A Schnabel, Vk Gadi

Cancer Res (2022) 82 (4_Supplement): PD9-09.

https://doi.org/10.1158/1538-7445.SABCS21-PD9-09

Published: 15 February 2022

View article titled, Abstract PD9-09: Breast cancer index and assessment of tumor proliferation by molecular grade index (MGI) within distinct HOXB13/IL17BR (H/I) subsets

Journal Articles

Abstract P5-13-31: Pik3ca mutations and myc amplification are associated with pathological complete response in human epidermal growth factor receptor 2-positive breast cancer patients receiving pyrotinib combined with trastuzumab neoadjuvant treatment

Qiyun Shi, Juncheng Xuhong, Jia Ge, Feng Liu, Yang Lan, Yi Zhang, Luo Tao, Xiuwu BIan, Xiaowei Qi, Jun Jiang

Cancer Res (2022) 82 (4_Supplement): P5-13-31.

https://doi.org/10.1158/1538-7445.SABCS21-P5-13-31

Published: 15 February 2022

View article titled, Abstract P5-13-31: Pik3ca mutations and myc amplification are associated with pathological complete response in human epidermal growth factor receptor 2-positive breast cancer patients receiving pyrotinib combined with trastuzumab neoadjuvant treatment

Journal Articles

Abstract 65: Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade

Cancer Res (2021) 81 (13_Supplement): 65.

https://doi.org/10.1158/1538-7445.AM2021-65

Published: 01 July 2021

View article titled, Abstract 65: Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade

Journal Articles

Abstract 1451: AN3025: A novel anti-human TNFR2 antibody that exhibits immune activation and strong anti-tumor activity in vivo

Yonglin Chen, Manxue Jia, Sherry Xu, Yanhui Zhao, Eric Chan, Meng Zhang, Emma Chen, Yi Zhang

Cancer Res (2021) 81 (13_Supplement): 1451.

https://doi.org/10.1158/1538-7445.AM2021-1451

Published: 01 July 2021

View article titled, Abstract 1451: AN3025: A novel anti-human TNFR2 antibody that exhibits immune activation and strong anti-tumor activity <em>in vivo</em>

Journal Articles

Abstract 1519: PD1 TurboCAR™ T cells: PD1-resistant CAR T cells with programmable cytokine signaling outputs

Regina Lin, Yi Zhang, Surabhi Srinivasan, Cecilia Lay, Shanshan Lang, Janette Sutton, Candice Manion, Tom Van Blarcom, Barbra Sasu, Siler Panowski

Cancer Res (2021) 81 (13_Supplement): 1519.

https://doi.org/10.1158/1538-7445.AM2021-1519

Published: 01 July 2021

View article titled, Abstract 1519: PD1 TurboCAR™ T cells: PD1-resistant CAR T cells with programmable cytokine signaling outputs

NARROW

Abstract 6226: Therapeutic vulnerability of MTAP-deleted nasopharyngeal carcinoma by MAT2A inhibitors

Abstract OT2-22-01: Epirubicin, cyclophosphamide and pyrotinib followed by docetaxel, trastuzumab and pyrotinib as neoadjuvant therapy for stage II-III HER2-positive breast cancer: a single-arm, multicenter phase 2 trial

Abstract P2-03-13: Breast Cancer Index (BCI) identifies fewer patients with high risk of late recurrence and high likelihood of benefit from extended endocrine therapy with invasive lobular compared to invasive ductal carcinoma

Abstract P2-11-10: Validation of the Breast Cancer Index (BCI) prognostic models optimized for late distant recurrence in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial

Abstract P2-03-02: Prospective assessment of the decision-making impact of the Breast Cancer Index in the BCI Registry Study

Abstract P5-02-52: Predictive and prognosis value of PIK3CA mutations in HER2-positive breast cancer treated with tyrosine kinase inhibitors (TKIs): a systemic review and meta-analysis

Abstract P5-10-01: Phase 2 study of anlotinib combined with taxanes and lobaplatin in the neoadjuvant treatment of triple-negative breast cancer: efficacy, safety and biomarker analysis from the SWH-B006 (neoALTALL) trial

Abstract GS1-06: Evaluation of the Breast Cancer Index in premenopausal women with early-stage HR+ breast cancer in the SOFT trial

Abstract P1-11-18: The efficacy and safety of trastuzumab and pertuzumab in combination with different chemotherapy regimens for neoadjuvant treatment of HER2-posotive breast cancer: a multi-center real-world study in China

And-1 Coordinates with the FANCM Complex to Regulate Fanconi Anemia Signaling and Cisplatin Resistance

Abstract 5499: Efficacy of icotinib as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE)

Abstract 6147: Immune population changes in mammary adipose tissue during the development of obesity and their influence on triple negative breast cancer progression

Abstract 4221: Characterization of OVA-expressing immunogenic syngeneic tumor models for immune checkpoint inhibitor evaluation

Abstract 421: PLX-3618, a potent, selective monovalent BRD4 degrader demonstrates activity in models of prostate cancer

Abstract PD15-04: Breast Cancer Index and assessment of the Net Treatment Benefit (NTB) of extended endocrine therapy in HR+ breast cancer

Abstract PD9-09: Breast cancer index and assessment of tumor proliferation by molecular grade index (MGI) within distinct HOXB13/IL17BR (H/I) subsets

Abstract P5-13-31: Pik3ca mutations and myc amplification are associated with pathological complete response in human epidermal growth factor receptor 2-positive breast cancer patients receiving pyrotinib combined with trastuzumab neoadjuvant treatment

Abstract 65: Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade

Abstract 1451: AN3025: A novel anti-human TNFR2 antibody that exhibits immune activation and strong anti-tumor activity in vivo

Abstract 1519: PD1 TurboCAR™ T cells: PD1-resistant CAR T cells with programmable cytokine signaling outputs

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only